Analysts Set Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Price Target at $22.22

Key Points

• Bicycle Therapeutics PLC (NASDAQ: BCYC) has received an average rating of "Moderate Buy" from nine research firms, with three holding and six buy recommendations.
• The stock is currently priced at $6.95 and has a market cap of $481.70 million, with a twelve-month price range between $6.10 and $28.67.
• In its latest quarterly earnings, Bicycle Therapeutics reported a loss of ($1.14) earnings per share, missing consensus estimates significantly, with revenue of only $2.90 million against expected earnings of $9.43 million.

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) has received an average recommendation of "Moderate Buy" from the nine ratings firms that are covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $22.2222.

Several analysts recently commented on BCYC shares. Morgan Stanley decreased their price target on shares of Bicycle Therapeutics from $17.00 to $13.00 and set an "equal weight" rating for the company in a report on Tuesday, August 12th. Oppenheimer restated an "outperform" rating and set a $44.00 price target (down from $48.00) on shares of Bicycle Therapeutics in a report on Monday, August 11th. Royal Bank Of Canada set a $27.00 target price on shares of Bicycle Therapeutics and gave the stock an "outperform" rating in a research report on Monday, August 11th. Finally, JMP Securities decreased their target price on shares of Bicycle Therapeutics from $22.00 to $10.00 and set a "market outperform" rating for the company in a research report on Tuesday, August 12th.

Bicycle Therapeutics Stock Performance

Shares of BCYC stock traded down $0.23 during trading on Wednesday, hitting $6.93. 259,411 shares of the company were exchanged, compared to its average volume of 218,142. The firm has a market capitalization of $480.32 million, a price-to-earnings ratio of -1.97 and a beta of 1.41. The business's 50-day simple moving average is $7.56 and its 200 day simple moving average is $7.99. Bicycle Therapeutics has a twelve month low of $6.10 and a twelve month high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last posted its quarterly earnings results on Friday, August 8th. The company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($0.95) by ($0.19). The company had revenue of $2.90 million for the quarter, compared to analyst estimates of $9.43 million. Bicycle Therapeutics had a negative return on equity of 32.43% and a negative net margin of 1,257.00%. On average, equities analysts forecast that Bicycle Therapeutics will post -3.06 earnings per share for the current fiscal year.

Institutional Trading of Bicycle Therapeutics

Several large investors have recently added to or reduced their stakes in the business. State of Tennessee Department of Treasury bought a new stake in Bicycle Therapeutics in the second quarter worth approximately $100,000. Soleus Capital Management L.P. bought a new stake in shares of Bicycle Therapeutics during the 2nd quarter worth $695,000. Monimus Capital Management LP bought a new stake in shares of Bicycle Therapeutics during the 2nd quarter worth $592,000. Rangeley Capital LLC bought a new stake in shares of Bicycle Therapeutics during the 2nd quarter worth $521,000. Finally, Moore Capital Management LP boosted its holdings in shares of Bicycle Therapeutics by 50.0% during the 2nd quarter. Moore Capital Management LP now owns 75,000 shares of the company's stock worth $521,000 after buying an additional 25,000 shares during the period. 86.15% of the stock is owned by institutional investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.